Multi-target kinase inhibitor, pharmaceutical composition, and preparation method for multi-target kinase inhibitor and use thereof
A multi-target kinase inhibitor is shown in formula (I), in which R is selected from formula (a), formula (b), formula (c), formula (d), formula (e) and formula (f). The multi-target kinase inhibitor can effectively inhibit the enzymatic activities of RET, VEGFR3 and PDGFRA, and can effectively treat diseases that are regulated and controlled by multi-target kinases and are related to abnormal signal transduction pathways of the multi-target kinases, including cancers of breast, respiratory tract, brain, reproductive organ, digestive tract, urinary tract, eye, liver, skin, head and/or neck and distant metastatic cancers thereof, and lymphoma, sarcoma, leukemia and the like. The active ingredients of the pharmaceutical composition of the present invention comprise a multi-target kinase inhibitor, which accounts for 1-50 wt % of the composition.
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof
wherein R is formula (a):
2. A method for preparing the compound or the pharmaceutically acceptable salt thereof according to claim 1 , comprising:
(1) reacting a compound of formula (II) with a compound of formula (III) to prepare a compound of formula (IV);
(2) reacting a compound of formula (IV) with a compound of formula (V) to prepare a compound of formula (VI); and
(3) reacting a compound of formula (VI) with a compound of formula (VII) to prepare the compound of formula (I);
the structural formulas of formula (II), formula (III), formula (IV), formula (V), formula (VI) and formula (VII) being shown as follows:
wherein R is formula (a).
3. A method for treating diseases caused by abnormal signal transduction pathways of RET, VEGFR3 and PDGFRA, comprising administering an effective amount of a composition to a subject in need thereof, wherein the composition comprises the compound or the pharmaceutically acceptable salt thereof according to claim 1 .
4. The method according to claim 3 , wherein the diseases caused by abnormal signal transduction pathways of RET, VEGFR3 and PDGFRA are cancers; the cancers are at least one of liver cancer, breast cancer, lung cancer, colorectal cancer, brain cancer, ovarian cancer, uterine tumor, prostate cancer, kidney cancer, melanoma, head and neck cancer, sarcoma, lymphoma and leukemia.
5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the pharmaceutically acceptable salt is a salt formed from the compound and an acid; the acid is methanesulfonic acid, hydrochloric acid, acetic acid, trifluoroacetic acid, tartaric acid, malic acid, citric acid, hydrobromic acid, phosphoric acid, sulfuric acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid or mandelic acid.
6. A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.
7. The pharmaceutical composition according to claim 6 , further comprising at least one pharmaceutical excipient known in the pharmaceutical art, wherein the pharmaceutical excipient includes one or more of a filler, a binder, a disintegrant, and a lubricating glidant.
8. The pharmaceutical composition according to claim 6 , wherein the compound or the pharmaceutically acceptable salt thereof accounts for 1-50 wt % of the pharmaceutical composition.
9. The pharmaceutical composition according to claim 7 , wherein the pharmaceutical excipient comprises 10-80 wt % of a filler, 1-45 wt % of a binder, 5-20 wt % of a disintegrant and 0.1-10 wt % of a lubricating glidant, based on the pharmaceutical composition.
10. The pharmaceutical composition according to claim 7 , wherein the filler is selected from at least one of lactose, microcrystalline cellulose, mannitol, sorbitol, calcium hydrogen phosphate, starch, pregelatinized starch, chitosan, sucrose, starch hydrolyzed oligosaccharides, and silicified microcrystalline cellulose; the binder is selected from at least one of hydroxypropyl methylcellulose, dextrin, carbomer, xanthan gum, gum arabic, sodium alginate, tragacanth, maltodextrin, polyvinylpyrrolidone, and hydroxypropyl cellulose; the disintegrant is selected from at least one of low-substituted hydroxypropyl cellulose, crospovidone, sodium croscarmellose, cross-linked sodium carboxymethyl starch and sodium carboxymethyl starch; the lubricating glidant is selected from at least one of magnesium stearate, calcium stearate, stearic acid, sodium fumarate, sodium dodecyl sulfate, glyceryl behenate, talc, silica, polyethylene glycol and sodium stearyl fumarate.
11. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition can be prepared in any pharmaceutically acceptable dosage form.
12. The pharmaceutical composition according to claim 11 , wherein the dosage form is an oral solid preparation.